WO2001002031A3 - Targeted anticalcification treatment - Google Patents

Targeted anticalcification treatment Download PDF

Info

Publication number
WO2001002031A3
WO2001002031A3 PCT/US2000/017606 US0017606W WO0102031A3 WO 2001002031 A3 WO2001002031 A3 WO 2001002031A3 US 0017606 W US0017606 W US 0017606W WO 0102031 A3 WO0102031 A3 WO 0102031A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
treatments
targeted agents
targeted
calcification
Prior art date
Application number
PCT/US2000/017606
Other languages
French (fr)
Other versions
WO2001002031A2 (en
Inventor
Dan Simionescu
Agneta Simionescu
Jean-Marie Girardot
Marie-Nadia Girardot
Original Assignee
Biomedical Design Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Design Inc filed Critical Biomedical Design Inc
Priority to AU56397/00A priority Critical patent/AU5639700A/en
Publication of WO2001002031A2 publication Critical patent/WO2001002031A2/en
Publication of WO2001002031A3 publication Critical patent/WO2001002031A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo

Abstract

Methods for providing biomaterials with increased resistance to calcification by treating with cell-targeted agents and/or with matrix-targeted agents. Cell-targeted agents are used which block calcium channels or which prevent oxidative damage to cells and/or inhibit enzymes. Other treatments of biomaterials may remove cell-derived calcium-binding components or target extracellular matrices, as by cleaving proteins with cyanogen bromide or reducing disulfide bonds to produce sulfhydryl groups which are thereafter alkylated. Combinations of the foregoing different treatments are also effective in increasing the calcification resistance of cardiovascular tissues that were previously subjected to chemical fixing and/or other anticalcification treatments.
PCT/US2000/017606 1999-07-01 2000-06-27 Targeted anticalcification treatment WO2001002031A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56397/00A AU5639700A (en) 1999-07-01 2000-06-27 Targeted anticalcification treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14217199P 1999-07-01 1999-07-01
US60/142,171 1999-07-01

Publications (2)

Publication Number Publication Date
WO2001002031A2 WO2001002031A2 (en) 2001-01-11
WO2001002031A3 true WO2001002031A3 (en) 2001-12-06

Family

ID=22498818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/017606 WO2001002031A2 (en) 1999-07-01 2000-06-27 Targeted anticalcification treatment

Country Status (2)

Country Link
AU (1) AU5639700A (en)
WO (1) WO2001002031A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900294B2 (en) 2002-01-04 2014-12-02 Colibri Heart Valve Llc Method of controlled release of a percutaneous replacement heart valve
US9119738B2 (en) 2010-06-28 2015-09-01 Colibri Heart Valve Llc Method and apparatus for the endoluminal delivery of intravascular devices

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078163B2 (en) 2001-03-30 2006-07-18 Medtronic, Inc. Process for reducing mineralization of tissue used in transplantation
US7955788B2 (en) 2003-10-30 2011-06-07 Medtronic, Inc. Bioprosthetic tissue preparation with synthetic hydrogels
SG10201601962WA (en) 2010-12-14 2016-04-28 Colibri Heart Valve Llc Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets
RU2597564C1 (en) * 2015-06-17 2016-09-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" (НИИ КПССЗ) Method for prediction of risk of calcification of biological prostheses of cardiac valves
WO2019051476A1 (en) 2017-09-11 2019-03-14 Incubar, LLC Conduit vascular implant sealing device for reducing endoleak

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
EP0564786A2 (en) * 1992-02-12 1993-10-13 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
WO1996013227A1 (en) * 1994-10-21 1996-05-09 University Of Michigan Calcification-resistant bioprosthetic tissue and methods of making same
US5558875A (en) * 1994-06-06 1996-09-24 Wang; Su Method of preparing collagenous tissue
US5843182A (en) * 1994-03-14 1998-12-01 Cryolife, Inc. Treated tissue for implantation and methods of preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
EP0564786A2 (en) * 1992-02-12 1993-10-13 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US5843182A (en) * 1994-03-14 1998-12-01 Cryolife, Inc. Treated tissue for implantation and methods of preparation
US5558875A (en) * 1994-06-06 1996-09-24 Wang; Su Method of preparing collagenous tissue
WO1996013227A1 (en) * 1994-10-21 1996-05-09 University Of Michigan Calcification-resistant bioprosthetic tissue and methods of making same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HENRY P D: "ANTI-ATHEROSCLEROTIC EFFECTS OF CALCIUM ANTAGONISTS: A BRIEF REVIEW", CLINICAL AND INVESTIGATIVE MEDICINE, vol. 10, no. 6, 1 November 1987 (1987-11-01), pages 601 - 605, XP000604021 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900294B2 (en) 2002-01-04 2014-12-02 Colibri Heart Valve Llc Method of controlled release of a percutaneous replacement heart valve
US9125739B2 (en) 2002-01-04 2015-09-08 Colibri Heart Valve Llc Percutaneous replacement heart valve and a delivery and implantation system
US9186248B2 (en) 2002-01-04 2015-11-17 Colibri Heart Valve Llc Percutaneously implantable replacement heart valve device and method of making same
US9554898B2 (en) 2002-01-04 2017-01-31 Colibri Heart Valve Llc Percutaneous prosthetic heart valve
US9119738B2 (en) 2010-06-28 2015-09-01 Colibri Heart Valve Llc Method and apparatus for the endoluminal delivery of intravascular devices

Also Published As

Publication number Publication date
WO2001002031A2 (en) 2001-01-11
AU5639700A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
AU1101801A (en) Compositions for treating shoes and methods and articles employing same
WO2004031350A3 (en) Modulation of forkhead box o1a expression
BR0210791A (en) Composition having bacteristatic and bactericidal activity against bacterial spores and vegetative cells and process for treating food using it.
EP1190099A4 (en) Antisense modulation of pi3k p85 expression
DE60231395D1 (en) DECELLULARIZATION OF TISSUE MATRIXES
WO2006121518A3 (en) Electrical devices, anti-scarring agents, and therapeutic compositions
WO2002103103A3 (en) Fluorine-containing compounds and polymers derived therefrom
CA2387198A1 (en) Method for treating hair loss using thyromimetic compounds
TR200201250T2 (en) Hydroxyiecosatetraenoate salts, their compositions and methods for their use in the treatment of dry eye disorders.
WO2001002031A3 (en) Targeted anticalcification treatment
AU5638200A (en) Tissue products having antiviral properties
WO2002030357A3 (en) Compounds and methods for modulating ccr4 function
PT1537274E (en) ENZYME PRESS FELT TREATMENT
WO2005089426A3 (en) Method of treating sepsis
UA94231C2 (en) Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm
MX2010003349A (en) Method of using composite enzyme for degumming jute (1).
CY1112119T1 (en) METHOD FOR COATING COATING
BR0210522A (en) Animal carcass treatment process
WO2003012031A3 (en) Antisense modulation of stearoyl-coa desaturase expression
WO2001084937A8 (en) Oxidoreductase mediated antimicrobial activity
PT1092040E (en) METHODS OF INHIBIT HELICOBACTER PYLORI
WO2005014607A3 (en) Antisense modulation of stearoyl-coa desaturase expression
CA2365313A1 (en) Method for eliminating legionella from a colonized aqueous flux by electropulsation, method for the treatment of an aqueous flux by electropulsation and use thereof in the elimination of legionella
AU2002233951A1 (en) Compositions for pre-treating shoes and methods and articles employing same
AU2001230243A1 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP